Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWCE | ISIN: CA58406U1012 | Ticker-Symbol: Y30
Frankfurt
20.12.24
16:00 Uhr
0,004 Euro
0,000
0,00 %
1-Jahres-Chart
MEDBRIGHT AI INVESTMENTS INC Chart 1 Jahr
5-Tage-Chart
MEDBRIGHT AI INVESTMENTS INC 5-Tage-Chart
GlobeNewswire (Europe)
246 Leser
Artikel bewerten:
(1)

MedBright AI Investments Inc.: MedBright AI Announces Rejuvenation Medical Group, a Large Canadian Clinic Group, as First International Customer for MedMatrix, the AI-Driven Data and Analytics Platform

Finanznachrichten News

VANCOUVER, British Columbia, Jan. 09, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the "Company" or "MedBright") (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) is pleased to announce that Rejuvenation medical group, a prominent dermatology group and a leader in advanced dermatological care, has decided to adopt MedMatrix across all its clinics in Canada. Renowned for its cutting-edge dermatology treatments and facilities, Rejuvenation medical group caters to over 750,000 patients each year. Their extensive network includes 9 clinics spread across 3 provinces in Canada. The group boasts a highly skilled team comprising 21 dermatologists, 5 Mohs surgeons, 2 plastic surgeons, and 13 general practitioners specializing in dermatology. This strategic implementation of MedMatrix is set to enhance their already formidable healthcare offerings.

For over 40 years, Rejuvenation medical group has established a reputation for excellence in providing comprehensive medical, surgical, cosmetic, and laser treatments. Under the guidance of esteemed dermatologists, the group is dedicated to delivering world-class services, ensuring every patient benefits from the highest standard of care.

Medbright AI is a significant shareholder in MedMatrix, an AI-powered data analytics platform. MedMatrix harnesses the power of artificial intelligence to evaluate and analyze key aspects of healthcare facilities, including patient needs and resource matching, revenue cycle management, patient demographics, facility geography, and competition. Through its advanced AI and data analytics capabilities, MedMatrix works alongside healthcare professionals to optimize each of these critical areas, resulting in more efficient clinic operations and improved patient outcomes.

"In an operation as large and complex as ours, there is a clear need for AI to help improve the patient experience and clinic revenue," said Paul Kuzel, MD, Medical Director and Dermatologist at Rejuvenation medical group. "We are excited to work with MedMatrix to improve our clinic operations across several areas in operations and research."

"Bringing Rejuvenation medical group and the entire team of highly talented medical professionals across their clinics as customers of the MedMatrix Platform is a major win for both sides," said Trevor Vieweg, CEO of Medbright. "The scale of Rejuvenation's operations make it a perfect opportunity to show the value of MedMatrix. We look forward to demonstrating the benefits of MedMatrix in clinic operations at Rejuvenation."

About MedBright AI Investments Inc.

MedBright AI is a capital allocator focused on investing in healthcare technology companies. The team at MedBright prides themselves on unparalleled access to opportunities, as well as structuring unique and advantageous investments. MedBright's mission is to construct a portfolio of synergistic investments to generate superior returns for shareholders. MedBright will focus on significant near-term and midterm high-quality opportunities with strong return potentials while maintaining commitment to governance. Click here to view the MedBright AI corporate video.

MedBright AI Investments Inc.
Trevor Vieweg, Chief Executive Officer
Email: investors@medbright.ai

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation, the anticipated benefits of MedMatrix such as increased clinic revenue, enhanced patient satisfaction, reduced wait times and physician burnout, including with respect to its use by Rejuvenation medical clin, and the Company's plans to generate returns for its shareholders through its portfolio of investments, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that MedMatrix will offer increased clinic revenue, enhanced patient satisfaction, reduced wait times and physician burnout, and that the Company will be able to generate returns for its shareholders. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that the use of MedMatrix will not result in increased clinic revenue, enhanced patient satisfaction, or reduced wait times and physician burnout, and the risk that the Company's portfolio of investments will not generate returns for shareholders.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.


© 2024 GlobeNewswire (Europe)
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.